Sox2 gene amplification significantly impacts overall survival in serous epithelial ovarian cancer

Jimmy Belotte, Nicole M. Fletcher, Mitchell Alexis, Robert T. Morris, Adnan R. Munkarah, Michael P. Diamond, Ghassan M. Saed

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Epithelial ovarian cancer (EOC) is the deadliest gynecologic cancer. Recently, the existence of ovarian cancer stem cells has been reported. Sox2, Nanog and Oct4 are key markers of "stemness". The objective of this study was to determine whether Sox2, Nanog, and Oct4 are associated with EOC and poor outcome. The expression of these markers was assessed by immunofluorescence staining and real-time RT-PCR in human EOC cell lines MDAH-2774 and SKOV-3, while the cancer genome atlas (TCGA) dataset was analyzed for associations with survival. Sox2, Nanog and Oct4 (POU5F1) were all detected by immunofluorescence staining and these results were confirmed by real-time RT-PCR. The TCGA dataset revealed a 26%, 9%, and 6% amplification of Sox2, Nanog and POU5F1, respectively. Additionally, K-M survival analyses showed a significant median overall survival difference (41 versus 48.3 months, P =.01) for Sox2 amplification, but not for Nanog (44.1 versus 36.2 months, P >.05) and POU5F1 (43.5 versus 45.0 months, P >.05). Our results suggest that Sox2 gene amplification significantly influences overall survival.

Original languageEnglish (US)
Pages (from-to)38-46
Number of pages9
JournalReproductive Sciences
Volume22
Issue number1
DOIs
StatePublished - Jan 23 2015

    Fingerprint

Keywords

  • Sox2 amplification
  • overall survival
  • serous epithelial ovarian cancer

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this